Notably, patients with high SLAMF8 expression who are single-positive for PD1 or CTLA4, or double-negative or double-positive for both markers, exhibit elevated immunotherapy scores, hinting at the potential for immunotherapy to benefit this subgroup of PCa patients (Fig. 7Q-T). This evidence concerns the gene SLAMF8 and posterior cortical atrophy.